OC
EDIT icon

Oppenheimer & Co’s Editas Medicine EDIT Stock Holding History

Oppenheimer & Co’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,736
Closed -$495K – 1508
2021
Q2 		$495K Buy
8,736
+2,546
+41% +$94K 0.01% 1039
2021
Q1 		$260K Buy
6,190
+3,024
+96% +$172K 0.01% 1244
2020
Q4 		$222K Buy
+3,166
New +$130K ﹤0.01% 1206
2018
Q4 		– Sell
-18,711
Closed -$595K – 1274
2018
Q3 		$595K Buy
+18,711
New +$605K 0.02% 796

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Oppenheimer & Co's EDIT Position: Q3 2021 in Review

Oppenheimer & Co sold out of Editas Medicine (EDIT) in Q3 2021, closing a stake of 8,736 shares — an estimated $495K sold.

Oppenheimer & Co first reported a position in EDIT in Q3 2018 and held it in 4 quarters. The position peaked at $595K in Q3 2018. 318 funds tracked by Wall St. Rank hold EDIT as of Q3 2021.

  • Oppenheimer & Co reported no remaining Editas Medicine position as of Q3 2021 after selling out during the quarter.
  • Oppenheimer & Co sold 8,736 Editas Medicine shares in Q3 2021, an estimated $495K.
  • Oppenheimer & Co first reported a position in Editas Medicine in Q3 2018 and held it in 4 quarters.
  • Oppenheimer & Co's Editas Medicine position peaked at $595K in Q3 2018.
  • 318 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2021.

Based on Oppenheimer & Co's 13F filing for Q3 2021, filed 12 Nov 2021.